Just as MDMA looked to be leading the charge of psychedelics and related compounds towards market for mental health conditions, a dose of jeopardy has been thrown into the mix.
The Institute for Clinical and Economic Review (ICER) - a non-profit that assesses the cost-effectiveness of medicines - has released a draft evidence report on the value provided by MDMA-AP as a treatment for post-traumatic stress disorder (PTSD).
Since MDMA is a banned substance, Lykos Therapeutics and its former self MAPS Public Benefit Corporation have faced plenty of challenges in attempting to take the drug through clinical trials and to the US market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze